We provide robust and sensitive in vitro screening and characterization platforms for accelerating the discovery and screening of potential therapies for Liver Injury. Our services enable comprehensive evaluation of candidate compounds by assessing their effects on hepatocyte viability, function, and response to injury. Key targets and pathways analyzed include cytochrome P450 enzymes, mitochondrial function, oxidative stress markers, and apoptotic signaling. We are equipped to investigate critical pathological processes such as hepatotoxicity, inflammation, oxidative stress, and cell death relevant to acute and chronic liver injury.
Our in vitro efficacy testing services for Liver Injury encompass a diverse array of assay platforms, including cell-based, enzymatic, and molecular detection methods. These assays are designed to measure cellular viability, enzymatic activity, biomarker expression, and molecular interactions, providing comprehensive insight into compound efficacy and toxicity profiles.
ATP assay: Measures cellular ATP levels as an indicator of cell viability and metabolic activity, commonly used to assess cytotoxicity in hepatocytes.
Acetyl-Arg-Gly-Lys (Ac)-7-amido-4-methylcoumarin as substrate: Utilizes a fluorogenic substrate to detect specific protease or enzymatic activities, aiding in the evaluation of cellular injury or enzyme inhibition.
Cell-based assay: Employs cultured liver cells to assess direct compound effects on cell health, function, and injury markers in a physiologically relevant context.
Chemiluminescent assay: Detects target molecules or enzyme activities using light emission, providing sensitive quantification of biomarkers or cellular responses.
Flow cytometry assay: Enables multiparametric analysis of individual cells, including viability, apoptosis, and surface marker expression, to profile injury mechanisms.
Fluorescent assay: Uses fluorescent probes or substrates to monitor cellular events, enzyme activities, or biomarker levels, offering rapid and quantitative analysis.
Luciferine/luciferase assay: Measures bioluminescence resulting from luciferase activity, often used for reporting gene expression or cell viability in hepatotoxicity studies.
RNA assay: Quantifies gene expression changes in response to treatment, enabling mechanistic insights into pathways activated during liver injury.
Radioactivity assay: Employs radiolabeled substrates or tracers to track molecular interactions or metabolic processes with high sensitivity.
SRC-1 peptide recruitment assay: Assesses the recruitment of steroid receptor coactivator-1 to nuclear receptors, informing on transcriptional regulation relevant to liver injury.
SRC-2-2 peptide recruitment assay: Evaluates the interaction of steroid receptor coactivator-2-2 with nuclear receptors, contributing to the understanding of gene regulation in hepatic responses.
We measure a range of pharmacological parameters such as potency, efficacy, binding affinity, and minimal effective or inhibitory concentrations. These parameters are critical for comparing candidate compounds, optimizing lead selection, and understanding therapeutic windows in drug development for liver injury.
EC-50: The concentration of a compound that produces 50% of its maximal effect, indicating potency in efficacy assays.
IC-50: The concentration required to inhibit a biological process or enzyme activity by 50%, used to assess inhibitory strength.
Kd: The equilibrium dissociation constant, reflecting the binding affinity between a compound and its target; lower Kd denotes stronger binding.
MEC: Minimum Effective Concentration, the lowest concentration at which a compound exerts a significant biological effect, important for dose selection.
MIC: Minimum Inhibitory Concentration, the smallest concentration that prevents a specified biological or microbial activity, relevant for assessing compound efficacy.
Cdc Like Kinase 1 (CLK1) is implicated in liver injury via regulation of RNA splicing and cellular stress responses. Testing CLK1 activity is crucial for evaluating potential drug-induced liver toxicity. Our service employs ATP and radioactivity assays to quantify CLK1 inhibition, providing precise IC-50 values. These data support early-stage drug development by identifying compounds that may modulate CLK1 activity and contribute to liver safety profiles.
| Pharmacological Activity | Material | Method | Parameter |
|---|---|---|---|
| Serine/threonine protein kinase (ClK1), inhibition | Human enzyme | Radioactivity assay | IC-50 |
| Serine/threonine protein kinase (ClK1), inhibition | Human enzyme | IC-50 | |
| Serine/threonine protein kinase (ClK1), inhibition | ATP assay | IC-50 | |
| Serine/threonine protein kinase (ClK1), inhibition | IC-50 |
Cdc Like Kinase 2 (CLK2) regulates RNA splicing and hepatocyte survival, making it a key target in liver injury research. Testing CLK2 activity is crucial for evaluating drug candidates’ effects on liver injury pathways. Our service employs sensitive radioactivity assays to measure CLK2 inhibition, providing quantitative IC-50 values. This enables precise assessment of compound potency, supporting the development of safer, more effective liver injury therapeutics.
| Pharmacological Activity | Material | Method | Parameter |
|---|---|---|---|
| Serine/threonine protein kinase (ClK2), inhibition | Human enzyme | Radioactivity assay | IC-50 |
| Serine/threonine protein kinase (ClK2), inhibition | Human enzyme | IC-50 |
E1A Binding Protein P300 is a transcriptional co-activator implicated in liver injury by regulating genes involved in inflammation and fibrosis. Testing its activity is crucial for evaluating therapeutic candidates in liver injury drug development. Our service employs a sensitive fluorescent assay to quantify p300 inhibition, providing precise IC-50 values to assess compound potency and efficacy. This enables informed decision-making in early-stage drug discovery.
| Pharmacological Activity | Material | Method | Parameter |
|---|---|---|---|
| Histone acetyltransferase P300 (HAT domain), inhibition | Recombinant enzyme | Fluorescent assay | IC-50 |
Histone Deacetylase 6 (HDAC6) plays a crucial role in liver injury by modulating cellular stress and inflammatory responses. HDAC6 testing is vital for evaluating drug candidates targeting liver injury, aiding in the identification of effective modulators. Our service uses a chemiluminescent assay with Acetyl-Arg-Gly-Lys (Ac)-7-amido-4-methylcoumarin as the substrate. Key parameters measured include EC-50, IC-50, and MIC, providing quantitative insights into compound potency and efficacy.
| Pharmacological Activity | Material | Method | Parameter |
|---|---|---|---|
| Histone deacetylase 6 degradation, induction | EC-50 | ||
| Histone deacetylase 6 expression, inhibition | AML12 mouse hepatocytes (paracetamol-treated) | Chemiluminescent assay | MIC |
| Histone deacetylase 6, inhibition | Acetyl-Arg-Gly-Lys (Ac)-7-amido-4-methylcoumarin as substrate | IC-50 |
Interleukin 1 Beta (IL-1β) is a key pro-inflammatory cytokine implicated in liver injury and drug-induced hepatotoxicity. Accurate IL-1β testing is crucial for evaluating inflammatory responses during liver injury drug development. Our service uses sensitive chemiluminescent and RNA assays to quantify IL-1β expression. The minimum inhibitory concentration (MIC) is a main parameter assessed, ensuring reliable measurement of drug effects on IL-1β-mediated liver inflammation.
| Pharmacological Activity | Material | Method | Parameter |
|---|---|---|---|
| Gene (interleukin-1 beta) transcription (endotoxin-induced), inhibition | Kupffer cells, rat | RNA assay | MIC |
| Gene (interleukin-1 beta) transcription (endotoxin-induced), inhibition | RAW264.7 mouse macrophages | RNA assay | MIC |
| Interleukin-1beta expression (endotoxin/ATP-induced), inhibition | Macrophages (THP1 human acute monocytic leukemia cells-derived) | Chemiluminescent assay | MIC |
| Interleukin-1beta expression (leptin-induced), inhibition | MCF7 human breast adenocarcinoma cells (hormone-dependent) | Chemiluminescent assay | MIC |
| Interleukin-1beta expression, inhibition | AML12 mouse hepatocytes (paracetamol-treated) | Chemiluminescent assay | MIC |
Janus Kinase 1 (JAK1) is a key mediator in inflammatory signaling pathways implicated in liver injury. Testing JAK1 activity is crucial for evaluating potential therapeutics targeting liver injury mechanisms. Our service utilizes a sensitive radioactivity assay to quantify JAK1 inhibition, providing precise measurement of IC-50 values. This enables effective assessment of drug candidates’ potency and supports informed decision-making in liver injury drug development.
| Pharmacological Activity | Material | Method | Parameter |
|---|---|---|---|
| Protein-tyrosine kinase (JAK1), inhibition | Human enzyme | Radioactivity assay | IC-50 |
| Protein-tyrosine kinase (JAK1), inhibition | Human enzyme | IC-50 |
Janus Kinase 2 (JAK2) plays a crucial role in inflammatory signaling pathways implicated in liver injury. Testing JAK2 activity is essential for evaluating potential drug candidates targeting liver diseases. Our service utilizes a sensitive radioactivity assay to measure JAK2 inhibition, determining the half-maximal inhibitory concentration (IC-50) as a key parameter. This enables precise assessment of compound efficacy in modulating JAK2-driven liver injury mechanisms during drug development.
| Pharmacological Activity | Material | Method | Parameter |
|---|---|---|---|
| Protein-tyrosine kinase (JAK2), inhibition | Human enzyme | Radioactivity assay | IC-50 |
| Protein-tyrosine kinase (JAK2), inhibition | Human enzyme | IC-50 |
Kelch Like Ech Associated Protein 1 (Keap1) regulates oxidative stress responses implicated in liver injury. Testing Keap1 is crucial in drug development to assess hepatotoxicity risk and antioxidant pathway activation. Key methods include Western blot, ELISA, and immunohistochemistry to quantify and localize Keap1. Main parameters measured are Keap1 protein levels, localization, and interactions with Nrf2, providing insight into oxidative stress modulation and potential drug-induced liver injury.
| Pharmacological Activity | Method | Parameter |
|---|---|---|
| Kelch-like ECH-associated protein 1 (INrf2) affinity | Biolayer interferometry assay | Kd |
| Kelch-like ECH-associated protein 1 (INrf2) affinity | Isothermal titration calorimetric assay | Kd |
Mitogen-Activated Protein Kinase Kinase Kinase 5 (MAP3K5) plays a key role in liver injury by regulating apoptosis and stress response pathways. Testing MAP3K5 activity is crucial for developing hepatoprotective drugs and assessing toxicity. Our service utilizes a sensitive radioactivity assay to measure MAP3K5 inhibition, providing precise IC-50 values for candidate compounds. This enables efficient screening and optimization of therapeutics targeting liver injury mechanisms.
| Pharmacological Activity | Material | Method | Parameter |
|---|---|---|---|
| Serine/threonine kinase (mitogen-activated protein kinase kinase kinase 5 [MAP3K5]), inhibition | Human enzyme | Radioactivity assay | IC-50 |
| Serine/threonine kinase (mitogen-activated protein kinase kinase kinase 5 [MAP3K5]), inhibition | Human enzyme | IC-50 |
Nfe2 Like Bzip Transcription Factor 2 (Nrf2) regulates cellular defense against oxidative stress, a key factor in liver injury. Testing Nrf2 activation is essential in drug development to assess hepatoprotective or hepatotoxic effects. Key methods include luciferin/luciferase, RNA, fluorescent, and chemiluminescent assays. Main parameters measured are MEC (minimum effective concentration), IC50 (half maximal inhibitory concentration), and MIC (minimum inhibitory concentration), enabling precise evaluation of drug safety and efficacy.
| Pharmacological Activity | Material | Method | Parameter |
|---|---|---|---|
| Gene (nuclear factor erythroid 2-related factor 2 (NRF2)) transcription, induction | HepG2 human hepatoblastoma cells transfected with antioxidant response element//luciferase | Luciferine/luciferase assay | MEC |
| Gene (nuclear factor erythroid 2-related factor 2 (NRF2)) transcription, induction | L02 human liver cells | RNA assay | MEC |
| Nuclear factor erythroid 2-related factor 2 (NRF2) expression decrease (tert-butylhydroperoxide-induced), inhibition | HepG2 human hepatoblastoma cells | Chemiluminescent assay | MIC |
| Nuclear factor erythroid 2-related factor 2 (NRF2)/Keap1 Kelch domain interaction, inhibition | Fluorescent assay | IC-50 | |
| Protein (nuclear factor erythroid 2-related factor 2 (NRF2)) expression, induction | HepG2 human hepatoblastoma cells | Chemiluminescent assay | MEC |
Nuclear Receptor Subfamily 1 Group H Member 4 (NR1H4), also known as FXR, regulates bile acid homeostasis and is pivotal in liver injury mechanisms. Testing NR1H4 activity is crucial for evaluating drug-induced liver injury risk. Key methods include SRC-1 and SRC-2-2 peptide recruitment assays, cell-based assays, luciferin/luciferase, and chemiluminescent assays. Main parameters measured are EC-50 and IC-50, indicating compound potency and inhibitory effects.
| Pharmacological Activity | Material | Method | Parameter |
|---|---|---|---|
| Farnesoid FXR receptor activation, induction | HepG2 human hepatoblastoma cells | SRC-1 peptide recruitment assay | EC-50 |
| Farnesoid FXR receptor activation, inhibition | SRC-2-2 peptide recruitment assay | IC-50 | |
| Farnesoid FXR receptor/SRC1 coactivator interaction, induction | Recombinant human receptor | Cell-based assay | EC-50 |
| Farnesoid FXR receptor/SRC1 coactivator interaction, induction | Recombinant human receptor | Chemiluminescent assay | EC-50 |
| Gene (FXR) transcription, induction | HepG2 human hepatoblastoma cells transfected with human receptor | Luciferine/luciferase assay | EC-50 |
| Gene transcription (FXR-dependent), induction | HEK293T human embryonic kidney cells transfected with FXR receptor | Luciferine/luciferase assay | EC-50 |
Pannexin 1 is implicated in mediating inflammation and cell death during liver injury. Testing its function is essential for evaluating potential therapeutics targeting liver damage mechanisms. Our Pannexin 1 testing service employs a sensitive flow cytometry assay to quantify channel activity and assess drug effects. Key parameters measured include the dissociation constant (Kd), providing critical insights into drug binding affinity and efficacy in liver injury drug development.
| Pharmacological Activity | Material | Method | Parameter |
|---|---|---|---|
| Pannexin-1 affinity | Dubca camel skin fibroblasts transfected with human protein | Flow cytometry assay | Kd |
| Pannexin-1 affinity | Dubca camel skin fibroblasts transfected with mouse protein | Flow cytometry assay | Kd |
Make Order
Experimental Scheme
Implementation
Conclusion